

SUPPLEMENTARY TABLES

Supplementary Table S1. Efficacy of the anti-SARS-Co-2 vaccination to prevent COVID-19 and death in patients over 60 years. The incidence rate (number of events per 1,000 person-days) from infection and death from COVID-19 in unvaccinated patients (n=552) and in patients with complete vaccination (n=6,068) is shown. Patients with complete vaccination were considered as those who had greater than or equal to 14 days after receipt of the second dose. Efficacy of vaccination (estimated as 1 minus the hazard ratio adjusted for covariates, expressed as percentage) to reduce risk of infection or death with its 95% confidence interval are presented.

Supplementary Table S2. Efficacy of the BNT162b2 and CoronaVac vaccines to prevent COVID-19 and death in patients over 60 years of age. The incidence rate (number of events per 1,000 person-days) from infection and death from COVID-19 in unvaccinated patients (n=552) and patients with complete vaccination with BNT162b2 (n=1,638) or CoronaVac (n=4,430) is shown. Patients with complete vaccination were considered as those who had greater than or equal to 14 days after receipt of the second dose. Efficacy of vaccination (estimated as 1 minus the hazard ratio adjusted for covariates, expressed as percentage) to reduce risk of infection or death with its 95% confidence interval are presented.

Supplementary Table S3. Efficacy of the anti-SARS-Co-2 vaccination to prevent COVID-19 and death in patients with diabetes. The incidence rate

(number of events per 1,000 person-days) from infection and death from COVID-19 in unvaccinated patients (n=238) and in patients with complete vaccination (n=1,947) is shown. Patients with complete vaccination were considered as those who had greater than or equal to 14 days after receipt of the second dose. Efficacy of vaccination (estimated as 1 minus the hazard ratio adjusted for covariates, expressed as percentage) to reduce risk of infection or death with its 95% confidence interval are presented.

Supplementary Table S4. Efficacy of the BNT162b2 and CoronaVac vaccines to prevent COVID-19 and death in patients with diabetes. The incidence rate (number of events per 1,000 person-days) from infection and death from COVID-19 in unvaccinated patients (n=238) and patients with complete vaccination with BNT162b2 (n=1,500) or CoronaVac (n=447) is shown. Patients with complete vaccination were considered as those who had greater than or equal to 14 days after receipt of the second dose. Efficacy of vaccination (estimated as 1 minus the hazard ratio adjusted for covariates, expressed as percentage) to reduce risk of infection or death with its 95% confidence interval are presented.

Supplementary Table S1.

Outcome and immunization status	Patients of 60 years or older	Patients with COVID-19 of 60 years or older		Vaccine efficacy		
	Number of person-days	Number of persons	Incidence rate (number of events / 1,000 person-days)	Age- and sex-adjusted analysis	Analysis adjusted for all variables	
COVID-19 diagnosis						
	Unvaccinated	107,756	89	0.826	-	-
	Complete vaccination	1,250,425	600	0.480	23.4% (14.4%-31.5%)	22.9% (13,8%-31,1%)
Deaths						
	Unvaccinated	114,763	39	0.340	-	-
	Complete vaccination	1,329,418	46	0.035	68.3% (60.8%-74.4%)	68.8% (61.3%-74.8%)

Supplementary Table S2.

Outcome and immunization status	Patients of 60 years or older	Patients with COVID-19 of 60 years or older		Vaccine efficacy		
	Number of person-days	Number of persons	Incidence rate (number of events / 1.000 person-days)	Age- and sex-adjusted analysis	Analysis adjusted for all variables	
COVID-19 diagnosis						
Unvaccinated	107,756	89	0.826	-	-	
Complete vaccination (BNT162b2 vaccine)	179,976	75	0.417	47.4% (27.2%-61.9%)	47.9% (27.9%-62.4%)	
Complete vaccination (CoronaVac vaccine)	1,070,449	525	0.490	22.1% (12.8%-30.4%)	21.6% (12.2%-30.0%)	
Deaths						
Unvaccinated	114,763	39	0.340	-	-	
Complete vaccination (BNT162b2 vaccine)	191,248	2	0.010	96.5% (85.2%-99.2%)	96.7% (86.0%-99.3%)	
Complete vaccination (CoronaVac vaccine)	1,138,170	44	0.039	66.6% (58.5%-73.1%)	66.9% (58.9%-73.4%)	

Supplementary Table S3.

Outcome and immunization status	Patients with diabetes	Patients with COVID-19 and diabetes		Vaccine efficacy		
	Number of person-days	Number of persons	Incidence rate (number of events / 1,000 person-days)	Age- and sex-adjusted analysis	Analysis adjusted for all variables	
COVID-19 diagnosis						
Unvaccinated	40,242	59	1.466	-	-	
Complete vaccination	361,925	314	0.868	21.2% (9.4%-31.5%)	23.8% (12.4%-33.8%)	
Deaths						
Unvaccinated	46,419	21	0.452	-	-	
Complete vaccination	406,390	23	0.057	65.1% (53.0%-74.1%)	68.8% (57.7%-77.1%)	

Supplementary Table S4.

Outcome and immunization status	Patients with diabetes	Patients with COVID-19 and diabetes		Vaccine efficacy		
	Number of person-days	Number of persons	Incidence rate (number of events / 1.000 person-days)	Age- and sex-adjusted analysis	Analysis adjusted for all variables	
COVID-19 diagnosis						
Unvaccinated	40,242	59	1.466	-	-	
Complete vaccination (BNT162b2 vaccine)	82,314	69	0.838	43.4% (19.4%-60.3%)	47.5% (24.7%-63.4%)	
Complete vaccination (CoronaVac vaccine)	279,611	245	0.876	19.2% (6.7%-30.1%)	22.3% (10.2%-32.8%)	
Deaths						
Unvaccinated	46,419	21	0.452	-	-	
Complete vaccination (BNT162b2 vaccine)	93,740	1	0.011	97.5% (80.7%-99.7%)	98.9% (88.6%-99.9%)	
Complete vaccination (CoronaVac vaccine)	312,650	22	0.070	60.9% (47.0%-71.2%)	64.8% (51.8%-74.2%)	